7.3 Future Innovations Oral GLP-1 and beyond: By 2026 and onward, the first GLP-1 pills will join injectables, with at least Novos Wegovy pill and Lillys pending oral candidates
The compound functions as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, two signaling systems that play central roles in endocrine regulation of metabolism
In animal research, increasing plasma adiponectin levels through pharmacological or genetic means has shown to alleviate obesity-induced endothelial dysfunction, hypertension, atherosclerosis, myocardial infarction, and diabetic cardiomyopathy
A review and update on melanocyte stimulating hormone therapy: afamelanotide
(2025), in Diabetes, Obesity and Metabolism, reported a weighted mean difference of 1.02 kg in lean body mass across 19 RCTs
Based on the route of administration, the cardiovascular drugs market is divided into oral, parenteral, and other route of administration